CN117338800A - 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活 - Google Patents

肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活 Download PDF

Info

Publication number
CN117338800A
CN117338800A CN202311449613.9A CN202311449613A CN117338800A CN 117338800 A CN117338800 A CN 117338800A CN 202311449613 A CN202311449613 A CN 202311449613A CN 117338800 A CN117338800 A CN 117338800A
Authority
CN
China
Prior art keywords
tumor
substance
alpha particle
administering
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311449613.9A
Other languages
English (en)
Chinese (zh)
Inventor
韦雷德·多曼克维奇
约纳·凯萨利
伊扎克·凯尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Tao Medical Co ltd
Original Assignee
Alfa Tao Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Tao Medical Co ltd filed Critical Alfa Tao Medical Co ltd
Publication of CN117338800A publication Critical patent/CN117338800A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1007—Arrangements or means for the introduction of sources into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1024—Seeds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1027—Interstitial radiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202311449613.9A 2018-11-01 2019-10-31 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活 Pending CN117338800A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862753930P 2018-11-01 2018-11-01
US62/753,930 2018-11-01
PCT/IB2019/059331 WO2020089819A1 (en) 2018-11-01 2019-10-31 Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
CN201980070966.3A CN112912137B (zh) 2018-11-01 2019-10-31 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980070966.3A Division CN112912137B (zh) 2018-11-01 2019-10-31 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活

Publications (1)

Publication Number Publication Date
CN117338800A true CN117338800A (zh) 2024-01-05

Family

ID=70464034

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311449613.9A Pending CN117338800A (zh) 2018-11-01 2019-10-31 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活
CN201980070966.3A Active CN112912137B (zh) 2018-11-01 2019-10-31 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980070966.3A Active CN112912137B (zh) 2018-11-01 2019-10-31 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活

Country Status (13)

Country Link
US (2) US12594291B2 (cg-RX-API-DMAC7.html)
EP (2) EP3873598B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022505022A (cg-RX-API-DMAC7.html)
KR (1) KR20210087949A (cg-RX-API-DMAC7.html)
CN (2) CN117338800A (cg-RX-API-DMAC7.html)
AU (3) AU2019370892B2 (cg-RX-API-DMAC7.html)
CA (1) CA3114299A1 (cg-RX-API-DMAC7.html)
ES (1) ES3035872T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250846T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072799T2 (cg-RX-API-DMAC7.html)
PL (1) PL3873598T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202102627PA (cg-RX-API-DMAC7.html)
WO (1) WO2020089819A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350431B2 (en) 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
CN116171152A (zh) * 2020-09-15 2023-05-26 昂科因凡特公司 制备的镭-224和子代联合dna修复抑制剂,用于放射性核素治疗
IL303002B1 (en) 2020-12-16 2026-08-01 Alpha Tau Medical Ltd Radiation therapy using scattered alpha emitters with enhanced beta therapy
CN113230400A (zh) * 2021-03-11 2021-08-10 上海交通大学 一种基于表观遗传调控的金纳米团簇放疗增敏组装体及其制备和应用
CA3211766A1 (en) 2021-03-19 2022-09-22 Gt Medical Technologies, Inc. Custom brachytherapy carriers
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US20220395701A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
US20220395703A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
JP2024521529A (ja) * 2021-06-20 2024-05-31 アルファ タウ メディカル リミテッド 免疫チェックポイント調節因子と組み合わせた腫瘍内アルファ放射体照射
EP4359071A4 (en) * 2021-06-20 2026-04-22 Alpha Tau Medical Ltd Intratumoral Alpha Emitter Radiation in Combination with Vascular System Inhibitors
US12053644B2 (en) 2021-12-30 2024-08-06 Gt Medical Technologies, Inc. Radiation shielding apparatus for implantable radioactive seeds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175206A1 (en) * 2000-06-16 2003-09-18 George Sgouros Liposomal encapsulation of chelated actinium-225 and uses thereof
CN101091794A (zh) * 2006-06-19 2007-12-26 博尔诚(北京)科技有限公司 用于预防和治疗转移性肿瘤的组合物
US20090088401A1 (en) * 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
CN102711454A (zh) * 2009-10-12 2012-10-03 杰西.L.S.奥 用于提高rna干扰剂的递送、表达或活性的方法和组合物
US20180214583A1 (en) * 2015-08-12 2018-08-02 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006243A2 (en) 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
CA2398678A1 (en) 2000-01-31 2001-08-09 Yissum Research Development Company Of The Hebrew University In Jerusalem Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
US20030153083A1 (en) 2000-01-31 2003-08-14 Alexei Shir Selective killing of cells by activation of double-stranded rna dependent protein kniase-pkr
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
WO2004045491A2 (en) 2002-11-18 2004-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
ATE424221T1 (de) 2003-04-30 2009-03-15 Univ Ramot Verfahren und vorrichtung für strahlentherapie
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
US7834064B2 (en) 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
HUE037796T2 (hu) 2005-07-26 2018-09-28 Aplha Tau Medical Ltd Radioaktív felületi forrás és eljárás elõállítására
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20110038888A1 (en) 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
US20090234628A1 (en) * 2008-03-14 2009-09-17 Siemens Medical Solutions Usa, Inc. Prediction of complete response given treatment data
US8821364B2 (en) 2008-09-02 2014-09-02 Battelle Memorial Institute Brachytherapy seed with fast dissolving matrix for optimal delivery of radionuclides to cancer tissue
PT3098239T (pt) 2008-12-22 2020-01-15 Targimmune Therapeutics Ag Vetor de rna de cadeia dupla dirigido ao egfr para o tratamento sistémico de cancro
US9642817B2 (en) 2009-08-27 2017-05-09 Technion Research & Development Foundation Limited Liposomal compositions and uses of same
EP2525835A4 (en) * 2010-01-18 2016-01-20 Univ Texas METHOD AND COMPOSITION FOR PARTICLE-CONTROLLED MEDICAMENTAL OUTPUT IN CANCER CELLS
TR201807294T4 (tr) * 2010-06-22 2018-06-21 Centre Nat Rech Scient Nükleik asit konjugatları için endosomolitik ajanlar ile optimize edilmiş in vivo aktarım sistemi.
CN104411331B (zh) 2012-01-13 2018-08-21 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN105031648A (zh) * 2015-08-25 2015-11-11 徐州医学院 新型靶向纳米粒子及其制备方法和用途
PT3319587T (pt) * 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
WO2017173101A1 (en) * 2016-03-30 2017-10-05 Virginia Commonwealth University Combination therapy for neuroblastoma using mda-7/il-24 with therapeutic agents
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CN110418651A (zh) * 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
WO2018042411A1 (en) 2016-09-04 2018-03-08 Alex Levitzki Management And Holdings, Ltd. Chimeric proteins for targeting dsrna
EP3321362A1 (en) * 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
WO2018183885A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
MX2019011945A (es) * 2017-04-05 2019-11-28 Boehringer Ingelheim Int Terapia de combinacion contra cancer.
SG11201910176PA (en) 2017-05-11 2019-11-28 Alpha Tau Medical Ltd Polymer coatings for brachytherapy devices
JP2020520368A (ja) 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ.エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
EP3688008A1 (en) 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
WO2019173456A1 (en) * 2018-03-06 2019-09-12 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
WO2019170890A1 (en) 2018-03-08 2019-09-12 Targimmune Therapeutics Ag A recombinant protein comprising a double stranded rna binding domain
CN116585625A (zh) 2018-03-08 2023-08-15 阿尔法陶医疗有限公司 放射治疗籽源和施药器
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP3856256A1 (en) * 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
SG11202109274TA (en) 2019-04-03 2021-10-28 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
MX2022002753A (es) 2019-10-10 2022-04-06 Alpha Tau Medical Ltd Preparacion humeda de fuentes de radioterapia.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175206A1 (en) * 2000-06-16 2003-09-18 George Sgouros Liposomal encapsulation of chelated actinium-225 and uses thereof
CN101091794A (zh) * 2006-06-19 2007-12-26 博尔诚(北京)科技有限公司 用于预防和治疗转移性肿瘤的组合物
US20090088401A1 (en) * 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
CN102711454A (zh) * 2009-10-12 2012-10-03 杰西.L.S.奥 用于提高rna干扰剂的递送、表达或活性的方法和组合物
US20180214583A1 (en) * 2015-08-12 2018-08-02 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer

Also Published As

Publication number Publication date
AU2019370892A1 (en) 2021-04-22
HRP20250846T1 (hr) 2025-09-12
AU2023208136B2 (en) 2025-06-12
WO2020089819A1 (en) 2020-05-07
CN112912137B (zh) 2023-11-21
AU2019370892B2 (en) 2023-04-27
JP2022505022A (ja) 2022-01-14
EP4603098A2 (en) 2025-08-20
JP2025013822A (ja) 2025-01-28
US20260191895A1 (en) 2026-07-09
EP3873598C0 (en) 2025-07-02
ES3035872T3 (en) 2025-09-10
PL3873598T3 (pl) 2025-11-17
KR20210087949A (ko) 2021-07-13
CN112912137A (zh) 2021-06-04
HUE072799T2 (hu) 2025-12-28
EP4603098A3 (en) 2025-09-03
US12594291B2 (en) 2026-04-07
EP3873598A4 (en) 2022-07-20
SG11202102627PA (en) 2021-05-28
CA3114299A1 (en) 2020-05-07
US20210379096A1 (en) 2021-12-09
EP3873598A1 (en) 2021-09-08
AU2023208136A1 (en) 2023-08-17
AU2025230719A1 (en) 2025-10-02
EP3873598B1 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
AU2023208136B2 (en) Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
Zhou et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer
Gong et al. Enhancing in situ cancer vaccines using delivery technologies
Cuzzubbo et al. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments
Yang et al. Multifunctional nanoparticle-loaded injectable alginate hydrogels with deep tumor penetration for enhanced chemo-immunotherapy of cancer
Han et al. Combination of Metal‐Phenolic Network‐Based Immunoactive Nanoparticles and Bipolar Irreversible Electroporation for Effective Cancer Immunotherapy
Domankevich et al. RIG-1-like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice
Cai et al. Improving cancer vaccine efficiency by nanomedicine
Jiang et al. Innate immune activation with multifunctional nanoparticles for cancer immunotherapy
Mahin et al. cGAS/STING in skin melanoma: from molecular mechanisms to therapeutics
Lee et al. Development of mRNA vaccines and their prophylactic and therapeutic applications
Chattopadhyay et al. A review on comprehending immunotherapeutic approaches inducing ferroptosis: Managing tumour immunity
Shi et al. In situ vaccines in the Era of cancer immunotherapy: conceptual innovation and clinical translation
Lee et al. Harnessing cGAS‐STING pathway for cancer immunotherapy: from bench to clinic
Li et al. The recent progress of tumor cell-derived exosomes in the pathogenesis, diagnosis and therapeutic strategies of tumors
RU2819734C2 (ru) Излучение внутриопухолевого альфа-излучателя и активация цитоплазматических рецепторов к внутриклеточному патогену
HK40049032A (en) Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
HK40101431A (en) Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
Zhu et al. Current progresses of functional nanomaterials for imaging diagnosis and treatment of melanoma
HK40049032B (en) Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
US20240285820A1 (en) Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators
Dhaval et al. Strategies to Develop Cancer Vaccines
HK40102661A (en) Intratumoral alpha-emitter radiation in combination with immune checkpoint regulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101431

Country of ref document: HK